Companies / Altis Labs
AI endpoints for oncology trials; IPRO model predicts survival from routine radiology scans (Nota platform).
altislabs.com| Round | Date | Amount | Investors |
|---|---|---|---|
| Series A | Sep 17, 2026 | US$25M | OrbiMed and Qiming Venture Partners USA (co-leads); Innovation Endeavors, Benchstrength, Fusion Fund, Lumira Ventures. Co-led by OrbiMed and Qiming Venture Partners USA; Innovation Endeavors, Benchstrength, Fusion Fund and Lumira Ventures (via the Cancer Breakthrough Fund) participated. Business Wire release dated Sep 17, 2026 from Toronto. |
| Seed | Jun 22, 2023 | US$6M | Benchstrength and Debiopharm Innovation Fund (co-leads). US$6M (C$7.9M) seed co-led by Benchstrength and the Debiopharm Innovation Fund with angels. Precedes the 2026 Series A. Primary not found: BetaKit only |
Data as of September 26, 2026. Suggest a correction